Bientôt des médicaments à base de cannabis en France?
The Minister of health, Marisol Touraine, asked the drug agency to study the possibility of marketing of derivatives of cannabis treatments.
An evolution of the treatments for chronic or progressive disease? Health Minister Marisol Touraine hopes that the drug (ANSM) Agency will study the dossier of a drug derived from the cannabis-based. Especially requested the Agency to focus on Sativex (Bayer), already available in most European countries to relieve some patients with multiple sclerosis.
"The therapeutic indication of this spray is pain and severe contractures and resistant (to other treatments, Editor's note) of some patients with multiple sclerosis (MS)", said from same source. However, so that a record of application for authorisation for placing on the market (AMM) can be filed with the ANSM, modification of a decree which prohibits using derivatives of cannabis therapeutic is necessary, explain to the Ministry.
The Minister recalled his opposition to the decriminalisation of cannabis
But "it will be at the Kangni to investigate the validity of this record (effectiveness, adverse... Editor's note) ", continued the Ministry" without prejudice to the final decision'. "It is a drug"and" Minister reminds again its firm opposition to the decriminalisation of cannabis ", stresses is still at the Department, then the magazine current values, which this approach on medical cannabis, quote Serge Lebigot, president of the association of Parents against drugs, for whom"the placing on the market of cannabis for therapeutic purposes is only the first step toward decriminalizing".
The Bayer laboratories Sativex is especially available to the Britain and the Canada where it is also used in advanced forms of cancer.
